509093-47-4 Usage
Uses
Used in Pharmaceutical Industry:
IRAK-1/4 INHIBITOR I is used as a research tool for studying the role of IRAK1 and IRAK4 in various cellular processes, particularly in the context of cancer development. It helps researchers understand the underlying mechanisms of these signaling pathways and their potential as therapeutic targets.
Used in Cancer Research:
IRAK-1/4 INHIBITOR I is used as an inhibitor in hepatoma cell lines and head and neck squamous cell carcinoma (HNSCC) cell lines to investigate its potential in inhibiting the growth and progression of these cancers. By blocking the activity of IRAK1, it may help in the development of novel therapeutic strategies for cancer treatment.
Used in Signal Transduction Studies:
IRAK-1/4 INHIBITOR I is used as a molecular probe to explore the intricate signaling networks involving IRAK1 and IRAK4. This helps in identifying potential drug targets and understanding the complex interactions between various signaling molecules, which can be crucial for the development of targeted therapies.
Biological Activity
irak-1-4 inhibitor i is an inhibitor of both irak-1 and irak-4 with ic50 values of 0.3μm and 0.2μm , respectively [1].il-1 receptor-associated kinases play important roles in signal transduction. there are totally four members of the iraks, they are irak-1, irak-2, irak-m and irak-4. irak-4 can activate nf-κb and mapk pathways and it is shown that the inhibition of irak-4 can be an anti-inflammatory therapy. irak-1-4 inhibitor i is an analog of an initial irak-4 inhibitor hit, which is screened out from a small molecule li brary against irak-4. with the less basic n-ethylenemorpholine moiety, irak-1-4 inhibitor i has a higher potency than other analogs. additionally, it does not show any cytotoxicity in a 72 h proliferation assay in hela cells(ed50 >30μm) [1].
Biochem/physiol Actions
IRAK1 overexpression leads to the development of head and neck squamous cell carcinoma (HNSCC). Therefore, IRAK-1/4 inhibitor I might be a potential therapeutic for HNSCC tumors. Various experimental studies states that IRAK-1/4 inhibitor might have a potential to exhibit?inhibitory effects on the nuclear factor (NF)-κB signaling pathway.
references
[1] jay p. powers, shyun li, juan c. jaen, jinqian liu, nigel p. c. walker, zhulun wang and holger wesche. discovery and initial sar of inhibitors of interleukin-1 receptor-associated kinase-4. bioorganic & medicinal chemistry letters. 2006, 16: 2842–2845.
Check Digit Verification of cas no
The CAS Registry Mumber 509093-47-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,9,0,9 and 3 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 509093-47:
(8*5)+(7*0)+(6*9)+(5*0)+(4*9)+(3*3)+(2*4)+(1*7)=154
154 % 10 = 4
So 509093-47-4 is a valid CAS Registry Number.
509093-47-4Relevant academic research and scientific papers
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4
Powers, Jay P.,Li, Shyun,Jaen, Juan C.,Liu, Jinqian,Walker, Nigel P.C.,Wang, Zhulun,Wesche, Holger
, p. 2842 - 2845 (2007/10/03)
High-throughput screening of a small-molecule compound library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-associated kinase-4.
Benzimidazole derivatives
-
, (2008/06/13)
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.
